Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease

Bibliography

• GOLD COPD guidelines. [Online]. Available from: http://www.goldcopd.org/Guidelines/guidelines-resources.html. 2014
   Google Scholar
• Fitch K, Iwasaki K, Pyenson B, et al. Variation in adherence with global initiative for chronic obstructive lung disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin 2011;27(7):1425-9
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65(8):719-25
   PubMed Web of Science ®Google Scholar
• Calverley P, Anderson J, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD: a systematic review. Chest 2008;133(5):1079-87
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD. part 2: reassessment in the larger Quebec cohort. Chest 2012;142(2):305-11
   PubMed Web of Science ®Google Scholar
• Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105(4):571-9
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
   PubMed Web of Science ®Google Scholar
• Decramer ML, Hanania NA, Lötvall JO, et al. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:53-64
   PubMed Web of Science ®Google Scholar
• Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis 2013;7(2):81-6
   PubMedGoogle Scholar
• Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med 2010;4(2):155-62
   PubMedGoogle Scholar
• Handley DA, Senanayake CH, Dutczak W, et al. Biological actions of formoterol isomers. Pulm Pharmacol Ther 2002;15(2):135-45
   PubMed Web of Science ®Google Scholar
• Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29(2):261-78
   PubMed Web of Science ®Google Scholar
• Kharidia J, Fogarty CM, LaForce CF, et al. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21(4):657-62
   PubMed Web of Science ®Google Scholar
• Sepracor U, Inc. MA. Brovana, package insert. [Online]. Available from: https://www.sunovionprofile.com/sp/brovana.html?utm_content=BRO_PTBTHOME&utm_source=BrandButton&utm_medium=website&utm_campaign=Brovana. 2014. Available from: https://www.sunovionprofile.com/sp/brovana.html
   Google Scholar
• Bauer A, McGlynn P, Bovet LL, et al. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir Care 2009;54(10):1342-7
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008;5(1):25-34
   PubMedGoogle Scholar
• Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121(5):1434-40
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189(3):250-5
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest 2014;146(6):1531-42
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hanania NA, Sciarappa KA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2008;2(2):37-48
   PubMedGoogle Scholar
• Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 2010;7(1):17-31
   PubMedGoogle Scholar
• Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009;103(4):516-24
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008;87(6):319-28
   PubMed Web of Science ®Google Scholar
• Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med 2008;102(2):189-97
   PubMed Web of Science ®Google Scholar
• Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003;97(9):1014-20
   PubMed Web of Science ®Google Scholar
• Hanania NA, Kalberg C, Yates J, et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005;18(1):19-22
   PubMed Web of Science ®Google Scholar
• Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61(2):122-8
   PubMed Web of Science ®Google Scholar
• Oppenheimer J. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelinesl. Ann Allergy, Asthma Immunol 2006;96:881. 10.1016/S1081-1206(10)61355-5
   Google Scholar
• Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest 2012;142(5):1126-33
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv 2013;26(3):174-9
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv 2014;27(2):103-9
   PubMed Web of Science ®Google Scholar
• Bollu V, Ernst FR, Karafilidis J, et al. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis 2013;8:631-9
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Klein GL, Colman SS, et al. Comparing COPD Treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am J Med 2007;120(5):435-41
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008;2(4):199-208
   PubMedGoogle Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107(10):1538-46
   PubMed Web of Science ®Google Scholar
• Panettieri RA, MacIntyre N, Sims M, et al. Comparison of the efficacy and safety of arformoterol 15 μg twice daily and arformoterol 30 μg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Clin Ther 2009;31(8):1716-23
   PubMed Web of Science ®Google Scholar